Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch + Lomb, a subsidiary of Bausch Health Companies (NYSE: BHC), will present new scientific data at the ARVO annual meeting from May 1-7, 2021. Highlights include one podium and 11 poster presentations on key products, including the investigational drug XIPERE™ and ongoing ARMOR study on antibiotic resistance. The ARMOR study features insights from 2009-2020 on ocular pathogens, while other presentations will cover recent findings from the pharmaceutical and surgical portfolios. This ongoing commitment to research aims to enhance treatment for eye care professionals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the successful election of 13 nominated directors at its annual meeting on April 27, 2021. Among the elected were Richard U. De Schutter and Sarah B. Kavanagh, receiving over 200 million votes for their positions. Shareholders also approved the compensation of named executive officers in a non-binding advisory vote and appointed PricewaterhouseCoopers LLP as the independent public accounting firm until the 2022 meeting. Full vote details will be reported to the SEC.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has announced the availability of its presentation for the Annual Meeting of Shareholders held on April 27, 2021. This presentation can be accessed via the Investor Relations section of Bausch Health's website. The company focuses on enhancing global health through its diverse healthcare products, including pharmaceuticals and medical devices primarily in eye health, gastroenterology, and dermatology.
Bausch Health Companies (NYSE/TSX: BHC) announced significant topline results from a pivotal Phase 3 trial of IDP-126, a new treatment for acne vulgaris. The trial met all three co-primary endpoints, demonstrating a treatment success rate of 50.5% compared to 20.5% for the vehicle. The study involved 193 participants and showed benefits as early as two weeks. If approved, IDP-126 would be the first-in-class treatment combining retinoid, anti-bacterial, and antibiotic properties. A New Drug Application is anticipated in the second half of 2022.
Bausch Health Companies (NYSE/TSX: BHC) announced six poster presentations at the virtual American Academy of Dermatology (AAD) Annual Meeting, running from April 23-25, 2021. Highlights include new analyses of ARAZLO® (tazarotene) Lotion, focusing on efficacy results from Phase 3 studies for moderate-to-severe acne. Presentations will also cover DUOBRII® (halobetasol propionate and tazarotene) Lotion's effectiveness and quality of life impacts in psoriasis, alongside evaluations of SILIQ® (brodalumab) Injection's long-term efficacy and safety. Scott Hirsch emphasized the commitment to demonstrating clinical benefits.
Bausch Health Companies Inc. announced on April 16, 2021, that its VYZULTA® (latanoprostene bunod ophthalmic solution) has received regulatory approval from ANVISA in Brazil. This marks the tenth approval for VYZULTA, which is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. With approvals in ten markets, including the U.S. and several Latin American countries, the company aims to address critical unmet medical needs in glaucoma treatment. Thomas J. Appio emphasized the commitment to further regulatory approvals.
Summary not available.
Summary not available.
Bausch Health and Novaliq announced successful results from the first Phase 3 trial (GOBI) of NOV03 for treating dry eye disease associated with meibomian gland dysfunction. The trial met both co-primary endpoints, achieving statistical significance in corneal staining and dryness scores at day 15, with continued positive results through day 57. Over 16 million U.S. adults suffer from dry eye disease, making this drug significant. Further studies (MOJAVE and KALAHARI) will assess safety and efficacy, potentially leading to FDA filing in 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the release of its first-quarter 2021 financial results on May 4, 2021, at 8:00 a.m. EDT. A conference call will be held to discuss these results along with a business update. Interested participants can access the call via a provided webcast link. Bausch Health focuses on developing health care products across various therapeutic areas, including eye health and gastroenterology. More information is available on their website.